Drug Database
TA

tamoxifen (tamoxifen, Douglas)

✓ Approved

Douglas Pharmaceuticals Limited · ESR1 · 小分子

什么是 tamoxifen?

tamoxifen 是一种小分子,由Douglas Pharmaceuticals Limited研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名tamoxifen, Douglas
公司Douglas Pharmaceuticals Limited
药物类别小分子
分子靶点ESR1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

tamoxifen 作用于 1 个分子靶点:

ESR1estrogen receptor 1 (ER, ESR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

tamoxifen 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved

相关研究文献

PubMedFrontiers in oncology2026-11-17

Ocular adverse event profiles associated with endocrine therapies for breast cancer: a global pharmacovigilance study using FAERS and VigiAccess.

Wang Xiaoping X, Zuo Wenzi W, Zhang Chengzhi C, Liu Ben B et al.

Ocular adverse events may affect tolerability during long-term endocrine therapy for breast cancer, but comparative real-world evidence remains limited. We characterized ocular adverse-event reporting patterns using the FDA Adverse Event Reporting System (FAERS) and VigiAccess. FAERS reports from Q1-2004 to Q1-2026 involving seven endocrine therapies were analyzed. Drug-specific signals were assessed using reporting odds ratio (ROR) and information component (IC) within a breast cancer indication-restricted, primary-suspect reference population. Class comparisons used multivariable logistic regression with Benjamini-Hochberg false-discovery-rate correction. Age, ovarian function suppression (OFS), and time to onset (TTO) were evaluated; VigiAccess was descriptive. Among 42,851 eligible reports, 2,528 contained ocular adverse events. Tamoxifen showed the broadest signal spectrum, while aromatase inhibitors (AIs) showed ocular-surface and posterior-segment signals. No ocular Preferred Terms met signal criteria for toremifene or elacestrant. FDR-adjusted comparisons showed broader retinal, macular, optic nerve, corneal, and vitreous reporting with selective estrogen receptor modulators (SERMs), particularly versus AIs. Among SERM users, age ≤45 years showed lower reporting odds than age 45-60 years (aOR 0.67, 95% CI 0.46-0.94). Concomitant OFS showed lower reporting odds among AI users (aOR 0.43, 95% CI 0.28-0.63), interpreted as exploratory. Median TTO was 79, 77, and 491 days for AIs, selective estrogen receptor degraders (SERDs), and SERMs. Ocular adverse-event reporting differed across endocrine therapies. These findings generate hypotheses for future pharmacoepidemiological, clinical, and mechanistic investigation but should not be interpreted as incidence, causality, or differential clinical risk.

PMID 43041374
阅读全文 →
PubMedBreast cancer research and treatment2026-11-15

Association between screen-detected health-related social needs and nonadherence to endocrine therapy in patients with nonmetastatic breast cancer: an observational study.

Liyanage-Don Nadia N, DeStephano David D, Sathe Claire C, Lee Shing S et al.

Endocrine therapy (ET) reduces recurrence and improves survival in patients with hormone receptor-positive breast cancer (BC), yet many patients are nonadherent. The impact of health-related social needs (HRSN) on ET nonadherence remains poorly understood. We extracted electronic health record data on patients with nonmetastatic BC followed at NewYork-Presbyterian/Columbia University Irving Medical Center. Patients were eligible if they were adults, prescribed ET, and screened for HRSN (food insecurity, housing instability, transportation needs). ET nonadherence during the 6 months after HRSN screening was determined using proportion of days covered (PDC), with PDC < 80% considered nonadherent. Logistic regression models estimated associations between each HRSN and ET nonadherence, adjusting for demographics, BC characteristics, medication count, and comorbidities. We identified 960 eligible BC patients between January 2022 and October 2024 (median age 67 [IQR 58-75] years, 99% female, 12% Black, 41% Hispanic, 38% non-English speaking, 67% publicly insured, 63% stage 0-I BC, 18% tamoxifen use, 13% chemotherapy use, 80% prescribed ≥ 3 medications). Overall, 275 (29%) patients were nonadherent to ET; 15% reported food insecurity, 10% housing instability, and 6% transportation needs. In adjusted analyses, housing instability (OR 1.97, 95% CI 1.11-3.46, p = 0.02) and transportation needs (OR 3.43, 95% CI 1.69-7.07, p < 0.01), but not food insecurity (OR 1.40, 95% CI 0.89-2.19, p = 0.15) were significantly associated with ET nonadherence. Housing instability and transportation needs were independently associated with higher odds of ET nonadherence in our sample. Screening for and addressing HRSN may represent an effective strategy for improving ET adherence and cancer-related outcomes.

PMID 43033306
阅读全文 →
PubMedCells2026-11-14

Beyond Aquaporins: Tamoxifen Preserves Collecting Duct Epithelial Homeostasis in Lithium-Induced Nephrogenic Diabetes Insipidus.

Centrone Mariangela M, Angelini Ines I, D'Agostino Mariagrazia M, Di Mise Annarita A et al.

Lithium is widely used to treat psychiatric disorders, including bipolar disorder. However, long-term lithium therapy is frequently associated with acquired nephrogenic diabetes insipidus (NDI), a disorder characterized by impaired urinary concentrating ability and excessive water loss. Tamoxifen (TAM), a selective estrogen receptor modulator, has previously been shown to alleviate lithium-induced NDI by restoring AQP2 and AQP3 expression. Here, we investigated whether necroptosis-related signaling, primary cilium remodeling, and epithelial-mesenchymal transition (EMT)-like changes contribute to lithium-induced collecting duct alterations and whether TAM modulates these responses. Using complementary in vitro, ex vivo, and in vivo approaches, we found that lithium significantly reduced the expression of the necroptosis-related proteins receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain-like protein (MLKL), whereas TAM prevented their downregulation. Lithium also induced primary cilium elongation and promoted EMT-like changes, characterized by reduced E-cadherin and increased vimentin expression, which were attenuated by TAM. Collectively, these findings demonstrate that lithium profoundly alters collecting duct epithelial homeostasis by modulating the abundance of necroptosis-related proteins, primary cilium morphology, and epithelial phenotype. The ability of TAM to counteract these alterations indicates that its protective effects extend beyond aquaporin regulation, supporting its potential as a therapeutic strategy for lithium-induced NDI.

PMID 43027311
阅读全文 →
PubMedInternational journal of molecular sciences2026-11-14

Alterations in the Expression of Tight and Adherens Junction Proteins in the Hen Oviduct Following Tamoxifen Treatment.

Frydrych Karolina K, Wolak Dominika D, Hrabia Anna A

Intercellular junctions are essential for maintaining epithelial integrity, barrier function, and tissue remodeling in the female reproductive system. However, their role in the avian oviduct is poorly understood. The aim of this study was to examine the effect of tamoxifen (TMX; an estrogen receptor blocker in birds) treatment on the histoarchitecture and the abundance of transcripts and proteins, as well as the immunolocalization of key tight junction proteins (occludin, claudin 1, and ZO1) and adherens junction proteins (E-cadherin and β-catenin) in the oviduct of hens. Tissue samples were collected from all oviductal segments (i.e., the infundibulum, magnum, isthmus, shell gland, and vagina) on day 8 of the experiment, from control (laying; n = 6) hens and hens treated (6 mg/kg body weight) daily with TMX (non-laying; n = 6). Following TMX treatment for 7 consecutive days, a pause in laying and partial oviductal regression was accompanied by segment-dependent alterations in mRNA transcript abundances (examined by qRT-PCR) and/or protein abundances (determined by Western blot) of the examined junctional molecules. Furthermore, TMX treatment altered the patterns of immunofluorescent staining within the oviductal wall, concomitant with the disorganization of the luminal epithelium and tubular glands. Our results suggest that the expression and localization of tight and adherens junction proteins in the hen oviduct depend strongly on estrogen signaling. Moreover, this study provides novel insights into the regulation of these proteins, indicating their potential involvement in the molecular mechanisms that orchestrate epithelial remodeling and functioning in the hen oviduct, which may affect poultry production.

PMID 43027984
阅读全文 →
PubMedBiochemical and biophysical research communications2026-11-14

Functional analysis of vitamin K converting enzyme UBIAD1 in cartilage formation using cartilage-specific knockout mice.

Hirashima Shunsuke S, Kuboki Eri E, Takayama Takuji T, Koiso Anna A et al.

UbiA prenyltransferase domain-containing protein 1 (UBIAD1) converts vitamin K congeners into vitamin K2 (MK-4). Our previous study demonstrated that early-life UBIAD1 deficiency causes osteogenesis imperfecta in tamoxifen-induced systemic UBIAD1 knockout mice (Hirashima S. et al., BBRC., 2024). The particularly evident cartilage abnormalities in systemic UBIAD1 knockout mice suggest that UBIAD1 plays a crucial role in cartilage formation. Therefore, we generated a chondrospecific UBIAD1 knockout mouse model and analyzed UBIAD1 role in cartilage formation. Methods: We generated a cartilage-specific UBIAD1 knockout mouse using a mouse line expressing Cre recombinase specifically in cartilage under type XI collagen-dependent regulation. The effects of UBIAD1 deficiency on bone formation were assessed through femur length and morphology evaluations, μCT-based bone density analysis, and histological examination of bone tissue specimens. Real-time RT-PCR was used to assess mRNA expression levels of chondrogenic factors in bone tissue, while LC-APCI-MS/MS quantified MK-4 concentration. Furthermore, primary chondrocytes were isolated from the femoral head, and their proliferation and differentiation potentials were assessed.

PMID 43025087
阅读全文 →
PubMedAnti-cancer agents in medicinal chemistry2026-11-13

Design, Synthesis, and Biological Evaluation of Benzothiazine Derivatives as New Anti-Breast Cancer Agents.

Movahed Mahsa Azami MA, Karimi Nafiseh N, Shahhosseini Soraya S, Zarghi Afshin A

Breast cancer is undeniably a common and potentially significant health issue, predominantly impacting women. It stands as the primary contributor to cancer-related fatalities. The connection between estrogen and breast cancer holds significant implications for the treatment process. Hormonal treatments, including Selective Estrogen Receptor Modulators (SERMs) such as tamoxifen, which regulate Estrogen Receptors (ER), are frequently used to treat breast cancer characterized by estrogen receptor positivity (ER-positive). In this study, a series of benzothiazine derivatives (5a-5j) were designed and synthesized as selective ER modulators, and their cytotoxic effects were examined. The designed benzothiazine derivatives were docked using the AutoDock Vina software in the human ER complexed with raloxifene. To synthesize the designed derivatives, saccharin sodium salt dihydrate and phenacyl bromide were used as starting materials, and analogs (5a-5j) were obtained via a multi-step synthesis. The produced compounds were purified, and their structures were validated through different spectroscopic data. The MTT assay was used to assess the cytotoxicity of each compound against human breast cancer cell lines, including MDA-MB-231 and MCF-7. Docking studies demonstrated that SERM compounds were bound to the human estrogen receptor's active site through hydrogen bonding with Asp-351 and His-524 as the key residues. The MTT results demonstrated that compound 5j, bearing allyl and morpholine substituents, indicated -8.3Kcal/mol affinity in docking and the highest cytotoxicity with an 83.2% and 66.6% inhibitory effect against the MCF-7 and MDA-MB231 cell lines, respectively. These findings suggest that all synthesized SERM analogs showed anti-proliferative activities at a 1 μM concentration compared to tamoxifen, preferably on the MCF-7 rather than the MDA-MB231 cell line. In summary, the findings of this study support that novel benzothiazine derivatives are a promising framework for anti-breast cancer agents. The outcome of this study may serve as a foundation for future investigation.

PMID 43021762
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多tamoxifen